OR WAIT 15 SECS
© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Taste-masking can ensure success of a drug product, particularly those targeted to pediatric or geriatric populations.
FDA approval rate speeds up despite COVID-19 complications.
Biologics and complex compounds are mapping the course for drug delivery solutions.
Equipment suppliers, CDMOs, and pharma collaborate to optimize manufacturing.
February 23, 2021
Through the acquisition, Catalent will establish pDNA development and manufacturing services at its Rockville, MD, facility and will gain Delphi’s team of R&D and genetic engineering scientists, technicians, and regulatory specialists.
Aprecia's compression-free 3DP manufacturing platform and Glatt’s multiparticulate technologies offer solutions to pharmaceutical dosage design challenges.
February 22, 2021
The companies will co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications.
With the acquisition, Eurofins gets Beacon’s G-protein coupled receptor research knowledge and its compound library.
February 18, 2021
The company has completed the expansion of its laboratory facilities to accommodate the development of APIs.
The companies have expanded their agreement to include the research and development of new therapies for influenza and other respiratory viruses.
February 17, 2021
The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.
February 15, 2021
Nanoform and Herantis have signed a biologics proof of concept agreement for formulation proof of concept projects aimed at improving nasal drug delivery to the brain.
February 10, 2021
The importance of characterizing excipients, supply chain security, and the role of novel excipients are explored.
Through the agreement, AbbVie will use Caribou’s next-generation Cas12a CRISPR hybrid RNA–DNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies.